Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. OLOPAN OPHTHALMIC SOLUTION 0.1% W/V [SIN16569P]

OLOPAN OPHTHALMIC SOLUTION 0.1% W/V [SIN16569P]

Active ingredients: OLOPAN OPHTHALMIC SOLUTION 0.1% W/V

Last updated 26 October 2025

Product Info

OLOPAN OPHTHALMIC SOLUTION 0.1% W/V

[SIN16569P]

Product information

Active Ingredient and Strength

OLOPATADINE HCL EQV OLOPATADINE - 1 MG/ML

Dosage Form

SOLUTION

Manufacturer and Country

BEXIMCO PHARMACEUTICALS LTD - BANGLADESH

Registration Number

SIN16569P

Licence Holder

GOLDPLUS UNIVERSAL PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

S01GX09

Therapeutic indications
OLOPAN eye drops is indicated for the treatment of the signs and symptoms of allergic conjunctivitis.

Posology and method of administration
Posology
The recommended dose is 1 drop in each affected eye 2 times per day.
Use in children
Safety and effectiveness in paediatric patients below the age of 3 years have not been established.
Use in patients with renal impairment
No studies have been performed in patients with renal impairment. No dosage regimen adjustment is required for patients with renal impairment.
Use in patients with hepatic impairment
No studies have been performed in patients with hepatic impairment. No dosage regimen adjustment is required for patients with hepatic impairment.
Use in patients 65 years of age or above
No dosage regimen adjustment is required in patients 65 years of age or above.
Method of administration
For ocular use.
After cap is removed, if tamper evident snap collar is loose, snap collar should be removed before using product.
To avoid contamination, the dropper tip should not touch any surface. The dropper tip should also not come into contact with the eye as this may cause injury to the eye. The bottle should be kept tightly closed when not in use. When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in a decrease in systemic side effect and increase in local activity. If more than one topical ophthalmic product is being used, the products must be administered at least 5 minutes apart. Eye ointments should be administered last. Patients should be advised not to wear a contact lens if their eye is red. OLOPATADINE should not be used for irritation caused by contact lens.

Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in Section List of Excipients – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.